President of the United States
A longstanding issue in the US is the high prices of prescription pharmaceuticals, with the average cost being 2.8 times higher than in other OECD countries, including estimated discounts and rebates. President Trump has vowed to lower drug prices by as much as 80 percent, and his latest executive
President of the United States
President Donald Trump has signed an executive order aiming to ease regulations and accelerate approvals for domestic pharmaceutical manufacturing in the United States. The move comes as the White House plans to assess tariffs on imported drugs, a decision that could have far-reaching consequences for patients. Industry experts warn that
President of the United States
President Donald Trump's latest attempt to bring down prescription drug prices has been met with fierce opposition from the pharmaceutical industry. In a post on Truth Social, Trump announced that he will sign an executive order on Monday, dubbing it the "Most Favored Nations" policy. This
Drugs
US President Donald Trump has vowed to drastically reduce pharmaceutical prices in the United States by implementing a "Most Favoured Nation" policy, where the cost of prescription drugs sold in the US would be pegged to the lowest price paid by other countries for the same drug. Trump
Pharmaceutical industry
China NT Pharma Group Company Limited, a pharmaceutical company in Hong Kong, has announced that it will acquire 100% of the issued shares in the Target Companies through a conditional agreement. The acquisition is valued at RMB116,219,960 (approximately HKD123,638,256) and will be satisfied by the allotment
Merck & Company Inc.
The US pharmaceutical company Merck has disclosed that it expects to pay an additional $200m in costs this year due to tariffs imposed by the Trump administration and retaliatory tariffs from foreign governments. The company cited a 10% tax on imports from around the world, as well as tariffs related
Drugs
President Trump's latest executive order on reducing pharmaceutical costs is not a new initiative, but rather a revival of policies from his first term and changes to programs started during the Biden administration. The order's implementation details are shrouded in uncertainty, but polling consistently shows that
Investment companies
KKR and Impilo have jointly acquired Immedica Pharma, a Stockholm-based pharmaceutical company focused on commercializing medicines for rare diseases and specialty care products. The acquisition supports Immedica's growth in the European rare disease space, with KKR and Impilo working together with the company's management team to
Bavarian Nordic A/S
The World Health Organization (WHO) has approved the first vaccine for the mpox virus, MVA-BN, in a bid to contain the ongoing outbreak. The vaccine has been added to WHO's prequalification list, making it available to communities in urgent need. The vaccine has shown an estimated 76% effectiveness
Pharmaceutical industry
Teva, a global pharmaceutical leader, has been recognized as one of the most sustainable companies in the world by TIME magazine and data firm Statista. The list of 500 companies measures how big and influential companies are living up to their promises to protect the planet. Teva's commitment
AstraZeneca PLC
Dr. Victoria L. Chiou, head of clinical excellence and innovation at AstraZeneca, has dedicated her career to revolutionizing cancer treatment. With a strong academic and research background, Chiou has led numerous organizational initiatives that have contributed to business transformation and future readiness through innovation, operational excellence, and sustainability. As a
Pharmaceutical industry
Nuvectis Pharma, a leader in precision oncology, has announced robust Q2 2024 financial results, solidifying its position as a trailblazer in the field. The company's flagship drugs, NXP800 and NXP900, are making significant strides in clinical trials, with patient enrollment at 15 sites in the US and UK.
